{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:38:48Z","timestamp":1784126328145,"version":"3.55.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007957","name":"Chongqing Municipal Education Commission","doi-asserted-by":"publisher","award":["KJ202102858619094"],"award-info":[{"award-number":["KJ202102858619094"]}],"id":[{"id":"10.13039\/501100007957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373966"],"award-info":[{"award-number":["82373966"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40262-025-01525-0","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:34:26Z","timestamp":1748457266000},"page":"973-986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension"],"prefix":"10.1007","volume":"64","author":[{"given":"Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjie","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6711-4251","authenticated-orcid":false,"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"1","key":"1525_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","volume":"10","author":"A Mocumbi","year":"2024","unstructured":"Mocumbi A, Humbert M, Saxena A, Jing Z-C, Sliwa K, Thienemann F, et al. Pulmonary hypertension. Nat Rev Dis Prim. 2024;10(1):1.","journal-title":"Nat Rev Dis Prim"},{"issue":"12S","key":"1525_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jacc.2004.02.037","volume":"43","author":"G Simonneau","year":"2004","unstructured":"Simonneau G, Gali\u00e8 N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12S):S5\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"1525_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1517\/14656560903164228","volume":"10","author":"R Ewert","year":"2009","unstructured":"Ewert R, Sch\u00e4per C, Halank M, Gl\u00e4ser S, Opitz CF. Inhalative iloprost\u2013pharmacology and clinical application. Expert Opin Pharmacother. 2009;10(13):2195\u2013207.","journal-title":"Expert Opin Pharmacother"},{"key":"1525_CR4","doi-asserted-by":"crossref","unstructured":"Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Dev Ther. 2012:19\u201328.","DOI":"10.2147\/DDDT.S19281"},{"key":"1525_CR5","doi-asserted-by":"crossref","unstructured":"Khan S, Randhawa S, Patail H, Spira Y, Frishman WH, Aronow WS, et al. Pharmacological update and emerging treatments of pulmonary hypertension. Cardiol Rev. 2024:10.1097.","DOI":"10.1097\/CRD.0000000000000647"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/VHRM.S321025","volume":"19","author":"JW Swisher","year":"2023","unstructured":"Swisher JW, Weaver E. The evolving management and treatment options for patients with pulmonary hypertension: current evidence and challenges. Vasc Health Risk Manag. 2023;19:103\u201326.","journal-title":"Vasc Health Risk Manag."},{"key":"1525_CR7","doi-asserted-by":"crossref","unstructured":"Dhand R. Intelligent nebulizers in the age of the Internet: The I-neb adaptive aerosol delivery (AAD) system. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA; 2010. pp. iii\u2013v.","DOI":"10.1089\/jamp.2010.0818"},{"key":"1525_CR8","doi-asserted-by":"crossref","unstructured":"Hardaker LE, Hatley RH. In vitro characterization of the I-neb adaptive aerosol delivery (AAD) system. J Aerosol Med Pulmon Drug Deliv. 2010;23(S1):S-11\u2013S-20.","DOI":"10.1089\/jamp.2009.0792"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"175346661983549","DOI":"10.1177\/1753466619835497","volume":"13","author":"T Gessler","year":"2019","unstructured":"Gessler T. lloprost delivered via the BREELIBTM nebulizer: a review of the clinical evidence for efficacy and safety. Ther Adv Respir Dis. 2019;13:1753466619835497.","journal-title":"Ther Adv Respir Dis"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/09031936.00166410","volume":"37","author":"BL Laube","year":"2011","unstructured":"Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir Soc. 2011;37:1308.","journal-title":"Eur Respir Soc"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amjms.2023.03.002","volume":"366","author":"K El-Kersh","year":"2023","unstructured":"El-Kersh K, Jalil BA. Pulmonary hypertension inhaled therapies: an updated review. Am J Med Sci. 2023;366:3\u201315.","journal-title":"Am J Med Sci"},{"issue":"2","key":"1525_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12063","volume":"12","author":"LA Spikes","year":"2022","unstructured":"Spikes LA, Bajwa AA, Burger CD, Desai SV, Eggert MS, El-Kersh KA, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension. Pulmon Circ. 2022;12(2): e12063.","journal-title":"Pulmon Circ."},{"key":"1525_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17460441.2024.2319049","volume":"19","author":"CH Rinderknecht","year":"2024","unstructured":"Rinderknecht CH, Ning M, Wu C, Wilson MS, Gampe C. Designing inhaled small molecule drugs for severe respiratory diseases: an overview of the challenges and opportunities. Expert Opin Drug Discov. 2024;19:1\u201314.","journal-title":"Expert Opin Drug Discov"},{"key":"1525_CR14","doi-asserted-by":"crossref","unstructured":"Darquenne C, Corcoran TE, Lavorini F, Sorano A, Usmani OS. The effects of airway disease on the deposition of inhaled drugs. Expert Opin Drug Deli. 2024 (just-accepted).","DOI":"10.1080\/17425247.2024.2392790"},{"issue":"5","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1089\/jamp.2023.29091.gt","volume":"36","author":"G Taylor","year":"2023","unstructured":"Taylor G. The pharmacokinetics of inhaled drugs. J Aerosol Med Pulm Drug Deliv. 2023;36(5):281\u20138.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"10","key":"1525_CR16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1080\/17425255.2018.1530215","volume":"14","author":"MG Matera","year":"2018","unstructured":"Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Metab Toxicol. 2018;14(10):1101\u201311.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40262-015-0250-x","volume":"54","author":"C Stockmann","year":"2015","unstructured":"Stockmann C, Roberts JK, Yellepeddi VK, Sherwin CM. Clinical pharmacokinetics of inhaled antimicrobials. Clin Pharmacokinet. 2015;54:473\u201392.","journal-title":"Clin Pharmacokinet"},{"key":"1525_CR18","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1208\/s12248-015-9733-9","volume":"17","author":"D Lu","year":"2015","unstructured":"Lu D, Lee SL, Lionberger RA, Choi S, Adams W, Caramenico HN, et al. International guidelines for bioequivalence of locally acting orally inhaled drug products: similarities and differences. AAPS J. 2015;17:546\u201357.","journal-title":"AAPS J"},{"key":"1525_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.addr.2018.06.003","volume":"133","author":"T Gessler","year":"2018","unstructured":"Gessler T. Inhalation of repurposed drugs to treat pulmonary hypertension. Adv Drug Deliv Rev. 2018;133:34\u201344.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","volume":"17","author":"Z Enlo-Scott","year":"2021","unstructured":"Enlo-Scott Z, B\u00e4ckstr\u00f6m E, Mudway I, Forbes B. Drug metabolism in the lungs: opportunities for optimising inhaled medicines. Expert Opin Drug Metab Toxicol. 2021;17(5):611\u201325.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejps.2015.08.009","volume":"80","author":"K Soulele","year":"2015","unstructured":"Soulele K, Macheras P, Silvestro L, Savu SR, Karalis V. Population pharmacokinetics of fluticasone propionate\/salmeterol using two different dry powder inhalers. Eur J Pharm Sci. 2015;80:33\u201342.","journal-title":"Eur J Pharm Sci"},{"key":"1525_CR22","doi-asserted-by":"publisher","first-page":"106055","DOI":"10.1016\/j.ejps.2021.106055","volume":"168","author":"C Tang","year":"2022","unstructured":"Tang C, Ou-Yang C-X, Chen W-J, Zou C, Huang J, Cui C, et al. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model. Eur J Pharm Sci. 2022;168:106055.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1525_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bcp.12999","volume":"82","author":"JM Borghardt","year":"2016","unstructured":"Borghardt JM, Weber B, Staab A, Kunz C, Kloft C. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. Br J Clin Pharmacol. 2016;82(3):739\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1525_CR24","first-page":"350","volume":"16","author":"C Shi","year":"2021","unstructured":"Shi C, Ignjatovi\u0107 J, Liu T, Han M, Cun D, \u0110uri\u0161 J, et al. In vitro-in vivo-in silico approach in the development of inhaled drug products: nanocrystal-based formulations with budesonide as a model drug. Asian J Pharm Sci. 2021;16(3):350\u201362.","journal-title":"Asian J Pharm Sci"},{"issue":"1","key":"1525_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jamp.2007.0657","volume":"21","author":"T Gessler","year":"2008","unstructured":"Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv. 2008;21(1):1\u201312.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"12S","key":"1525_CR26","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.jacc.2004.02.029","volume":"43","author":"M Humbert","year":"2004","unstructured":"Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12S):S13\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1525_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1592\/phco.30.7.728","volume":"30","author":"MS Buckley","year":"2010","unstructured":"Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010;30(7):728\u201340.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1525_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1183\/09031936.00097107","volume":"31","author":"M Gomberg-Maitland","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31(4):891\u2013901.","journal-title":"Eur Respir J"},{"key":"1525_CR29","doi-asserted-by":"publisher","first-page":"j5492","DOI":"10.1136\/bmj.j5492","volume":"360","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.","journal-title":"BMJ"},{"issue":"3","key":"1525_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1067\/mtc.2003.107","volume":"125","author":"M Hach\u00e9","year":"2003","unstructured":"Hach\u00e9 M, Denault A, B\u00e9lisle S, Robitaille D, Couture P, Sheridan P, et al. Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. J Thorac Cardiovasc Surg. 2003;125(3):642\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"1525_CR31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1365-2125.2012.04301.x","volume":"74","author":"LB Nicolas","year":"2012","unstructured":"Nicolas LB, Krause A, Gutierrez MM, Dingemanse J. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects. Br J Clin Pharmacol. 2012;74(6):978\u201389.","journal-title":"Br J Clin Pharmacol"},{"key":"1525_CR32","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s13346-020-00874-6","volume":"11","author":"PP Mehta","year":"2021","unstructured":"Mehta PP, Dhapte-Pawar VS. Repurposing drug molecules for new pulmonary therapeutic interventions. Drug Deliv Transl Res. 2021;11:1829\u201348.","journal-title":"Drug Deliv Transl Res"},{"issue":"111","key":"1525_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1183\/09059180.00011111","volume":"18","author":"H Olschewski","year":"2009","unstructured":"Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009;18(111):29\u201334.","journal-title":"Eur Respir Rev"},{"key":"1525_CR34","doi-asserted-by":"crossref","unstructured":"Skuballa W, Rad\u00fcchel B, Vorbr\u00fcggen H, editors. Chemistry of stable prostacyclin analogues: synthesis of iloprost. Prostacyclin and its stable analogue Iloprost. Berlin: Springer; 1987.","DOI":"10.1007\/978-3-642-71499-3_2"},{"issue":"2","key":"1525_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/2045893217706691","volume":"7","author":"T Gessler","year":"2017","unstructured":"Gessler T, Ghofrani H-A, Held M, Klose H, Leuchte H, Olschewski H, et al. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmon Circ. 2017;7(2):505\u201313.","journal-title":"Pulmon Circ."},{"issue":"4","key":"1525_CR36","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","volume":"124","author":"H Olschewski","year":"2003","unstructured":"Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest. 2003;124(4):1294\u2013304.","journal-title":"Chest"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/BF00614197","volume":"30","author":"W Krause","year":"1986","unstructured":"Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1986;30:61\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1525_CR38","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134.","journal-title":"Am J Respir Crit Care Med"},{"key":"1525_CR39","doi-asserted-by":"crossref","unstructured":"Nelsen AC, Laliberte KJ, Zaccardelli DS, Gotzkowsky SK. Pharmacokinetics of inhaled treprostinil sodium in healthy volunteers. B58 treatment of pulmonary arterial hypertension: American Thoracic Society; 2010. p. A3348-A.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A3348"},{"key":"1525_CR40","doi-asserted-by":"crossref","unstructured":"Cassady SJ, Almario JAN, Ramani GV. Therapeutic potential of treprostinil inhalation powder for patients with pulmonary arterial hypertension: evidence to date. Drug Healthc Patient Saf. 2024:51\u20139.","DOI":"10.2147\/DHPS.S372239"},{"key":"1525_CR41","doi-asserted-by":"publisher","first-page":"102266","DOI":"10.1016\/j.pupt.2023.102266","volume":"83","author":"C McEvoy","year":"2023","unstructured":"McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, et al. Tyvaso DPI: drug-device characteristics and patient clinical considerations. Pulmon Pharmacol Ther. 2023;83:102266.","journal-title":"Pulmon Pharmacol Ther."},{"issue":"12","key":"1525_CR42","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","volume":"55","author":"P Kumar","year":"2016","unstructured":"Kumar P, Thudium E, Laliberte K, Zaccardelli D, Nelsen A. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokinet. 2016;55(12):1495\u2013505.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1525_CR43","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jacc.2006.05.070","volume":"48","author":"RN Channick","year":"2006","unstructured":"Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48(7):1433\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1525_CR44","first-page":"204589402097150","volume":"10","author":"R Roscigno","year":"2020","unstructured":"Roscigno R, Vaughn T, Anderson S, Wargin W, Hunt T, Hill NS. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil. Pulmon Circ. 2020;10(4):2045894020971509.","journal-title":"Pulmon Circ."},{"key":"1525_CR45","doi-asserted-by":"crossref","unstructured":"El-Kersh K, Restrepo Jaramillo R, Joly J, Pearce N, Deng C, Miceli M. Comparison of pharmacokinetics of 3 doses of treprostinil inhalation powder (Tyvaso DPI) and 3 doses of Tyvaso in healthy normal volunteers. B53 marina: learning from ph registries and clinical trials: American Thoracic Society; 2022. p. A3055-A.","DOI":"10.1164\/ajrccm-conference.2022.205.1_MeetingAbstracts.A3055"},{"key":"1525_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2021.102002","volume":"65","author":"RW Chapman","year":"2020","unstructured":"Chapman RW, Corboz MR, Malinin VS, Plaunt AJ, Konicek DM, Li Z, et al. An overview of the biology of a long-acting inhaled treprostinil prodrug. Pulm Pharmacol Ther. 2020;65: 102002.","journal-title":"Pulm Pharmacol Ther"},{"key":"1525_CR47","doi-asserted-by":"crossref","unstructured":"Nguyen T, Chang C, Cipolla D, Malinin V, Perkins W, Viramontes V, et al. Treprostinil palmitil inhalation powder leverages endogenous lung enzymes to provide sustained treprostinil. Expert Opin Drug Deliv. 2024 (just-accepted).","DOI":"10.1080\/17425247.2024.2395444"},{"issue":"7","key":"1525_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/17425247.2021.1873271","volume":"18","author":"MG Matera","year":"2021","unstructured":"Matera MG, Calzetta L, Ora J, Rogliani P, Cazzola M. Pharmacokinetic\/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opin Drug Deliv. 2021;18(7):891\u2013906.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"1525_CR49","first-page":"5144","volume":"39","author":"FA Ismat","year":"2022","unstructured":"Ismat FA, Usansky HH, Villa R, Zou J, Teper A. Safety, tolerability, and pharmacokinetics of treprostinil palmitil inhalation powder for pulmonary hypertension: a phase 1, randomized, double-blind, single-and multiple-dose study. Adv Ther. 2022;39(11):5144\u201357.","journal-title":"Adv Ther"},{"issue":"4","key":"1525_CR50","doi-asserted-by":"publisher","first-page":"A2162","DOI":"10.1016\/j.chest.2020.08.1860","volume":"158","author":"A Keogh","year":"2020","unstructured":"Keogh A, Dwyer N, Kotlyar E, Kaye D, Maurer M, Weers J, et al. Acute hemodynamic improvement in chronic pulmonary arterial hypertension on dual therapy following RT234 inhalation. Chest. 2020;158(4):A2162\u20133.","journal-title":"Chest"},{"issue":"4","key":"1525_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/jamp.2020.1651","volume":"34","author":"MA Eldon","year":"2021","unstructured":"Eldon MA, Parsley EL, Maurer M, Tarara TE, Okikawa J, Weers JG. Safety, tolerability, and pharmacokinetics of RT234 (vardenafil inhalation powder): a first-in-human, ascending single-and multiple-dose study in healthy subjects. J Aerosol Med Pulm Drug Deliv. 2021;34(4):251\u201361.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"9","key":"1525_CR52","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1177\/0091270005276847","volume":"45","author":"M Gupta","year":"2005","unstructured":"Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005;45(9):987\u20131003.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1525_CR53","first-page":"2732017","volume":"2018","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018(1):2732017.","journal-title":"Can Respir J"},{"issue":"6","key":"1525_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S0002-9629(15)41723-9","volume":"311","author":"JB Shipley","year":"1996","unstructured":"Shipley JB, Tolman D, Hastillo A, Hess ML. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci. 1996;311(6):286\u201391.","journal-title":"Am J Med Sci"},{"key":"1525_CR55","doi-asserted-by":"crossref","unstructured":"Nguyen AQ-N, Denault AY, Th\u00e9oret Y, Varin F. Inhaled milrinone in cardiac surgical patients: pharmacokinetic and pharmacodynamic exploration. Sci Rep. 2023;13(1):3557.","DOI":"10.1038\/s41598-023-29945-7"},{"issue":"10","key":"1525_CR56","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/jps.2600731029","volume":"73","author":"RM Stroshane","year":"1984","unstructured":"Stroshane RM, Koss RF, Biddlecome CE, Luczkowec C, Edelsonx J. Oral and intravenous pharmacokinetics of milrinone in human volunteers. J Pharm Sci. 1984;73(10):1438\u201341.","journal-title":"J Pharm Sci"},{"issue":"7","key":"1525_CR57","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551\u201369.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1525_CR58","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ijcard.2011.02.024","volume":"159","author":"K Nakamura","year":"2012","unstructured":"Nakamura K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D, et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2012;159(2):100\u20136.","journal-title":"Int J Cardiol"},{"key":"1525_CR59","doi-asserted-by":"crossref","unstructured":"Thomas MJ, Bonneau O, Ciuclan L, Duggan N, Rowlands D, Grieve J, et al. Imatinib as a therapy for pulmonary arterial hypertension-insights into mechanism of action from rodent models. B63 experimental models in pulmonary hypertension I: American Thoracic Society; 2012. p. A3420-A.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A3420"},{"issue":"2","key":"1525_CR60","doi-asserted-by":"publisher","first-page":"00433-2022","DOI":"10.1183\/23120541.00433-2022","volume":"9","author":"H Gillies","year":"2023","unstructured":"Gillies H, Niven R, Dake BT, Chakinala MM, Feldman JP, Hill NS, et al. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. ERJ Open Res. 2023;9(2):00433\u20132022.","journal-title":"ERJ Open Res."},{"issue":"4","key":"1525_CR61","first-page":"204589402110570","volume":"11","author":"RP Frantz","year":"2021","unstructured":"Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, et al. TORREY, a phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. Pulmon Circ. 2021;11(4):20458940211057070.","journal-title":"Pulmon Circ."},{"issue":"16","key":"1525_CR62","doi-asserted-by":"publisher","first-page":"12653","DOI":"10.3390\/ijms241612653","volume":"24","author":"SS Pullamsetti","year":"2023","unstructured":"Pullamsetti SS, Sitapara R, Osterhout R, Weiss A, Carter LL, Zisman LS, et al. Pharmacology and rationale for seralutinib in the treatment of pulmonary arterial hypertension. Int J Mol Sci. 2023;24(16):12653.","journal-title":"Int J Mol Sci"},{"key":"1525_CR63","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2147\/COPD.S454905","volume":"19","author":"EK Bajwa","year":"2024","unstructured":"Bajwa EK, Cislak D, Kumar A, Li D, Messina EJ, Reynders T, et al. Phase 1 study of MK-5475, an inhaled soluble guanylate cyclase stimulator, in participants with pulmonary hypertension associated with chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulmon Dis. 2024;19:1105\u201321.","journal-title":"Int J Chronic Obstruct Pulmon Dis."},{"key":"1525_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40262-014-0201-y","volume":"54","author":"PJ Rix","year":"2015","unstructured":"Rix PJ, Vick A, Attkins NJ, Barker GE, Bott AW, Alcorn H, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects. Clin Pharmacokinet. 2015;54:261\u201372.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1525_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014504","volume":"6","author":"RM Pluta","year":"2011","unstructured":"Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, DeVroom HL, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS ONE. 2011;6(1): e14504.","journal-title":"PLoS ONE"},{"issue":"2","key":"1525_CR66","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","volume":"44","author":"K Laliberte","year":"2004","unstructured":"Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin\u00ae) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209\u201314.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"1525_CR67","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00000542-199409000-00014","volume":"81","author":"JM Bailey","year":"1994","unstructured":"Bailey JM, Levy JH, Kikura M, Szlam F, Hug CC Jr. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anesthesiology. 1994;81(3):616\u201322.","journal-title":"Anesthesiology"},{"issue":"2","key":"1525_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0091270003262101","volume":"44","author":"B Peng","year":"2004","unstructured":"Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, et al. Absolute bioavailability of imatinib (Glivec\u00ae) orally versus intravenous infusion. J Clin Pharmacol. 2004;44(2):158\u201362.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1525_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.toxlet.2009.06.865","volume":"190","author":"CC Hunault","year":"2009","unstructured":"Hunault CC, van Velzen AG, Sips AJ, Schothorst RC, Meulenbelt J. Bioavailability of sodium nitrite from an aqueous solution in healthy adults. Toxicol Lett. 2009;190(1):48\u201353.","journal-title":"Toxicol Lett"},{"issue":"6","key":"1525_CR70","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1046\/j.1365-2125.1996.00493.x","volume":"42","author":"BJ Lipworth","year":"1996","unstructured":"Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996;42(6):697\u2013705.","journal-title":"Br J Clin Pharmacol"},{"key":"1525_CR71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jaerosci.2016.08.005","volume":"101","author":"SK Devi","year":"2016","unstructured":"Devi SK, Panchagnula MV, Alladi M. Designing aerosol size distribution to minimize inter-subject variability of alveolar deposition. J Aerosol Sci. 2016;101:144\u201355.","journal-title":"J Aerosol Sci"},{"issue":"12","key":"1525_CR72","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425247.2018.1544616","volume":"15","author":"AR Martin","year":"2018","unstructured":"Martin AR, Moore CP, Finlay WH. Models of deposition, pharmacokinetics, and intersubject variability in respiratory drug delivery. Expert Opin Drug Deliv. 2018;15(12):1175\u201388.","journal-title":"Expert Opin Drug Deliv"},{"issue":"3","key":"1525_CR73","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/S0022-5347(25)00213-7","volume":"241","author":"R Richards","year":"1987","unstructured":"Richards R, Dickson C, Renwick A, Lewis R, Holgate S. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther. 1987;241(3):1028\u201332.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9229","key":"1525_CR74","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(00)02581-2","volume":"356","author":"MH Brutsche","year":"2000","unstructured":"Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356(9229):556\u201361.","journal-title":"Lancet"},{"issue":"7","key":"1525_CR75","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/MNM.0b013e328339ea9b","volume":"31","author":"K Suga","year":"2010","unstructured":"Suga K, Tokuda O, Okada M, Koike M, Iwanaga H, Matsunaga N. Assessment of cross-sectional lung ventilation\u2013perfusion imbalance in primary and passive pulmonary hypertension with automated V\/Q SPECT. Nucl Med Commun. 2010;31(7):673\u201381.","journal-title":"Nucl Med Commun"},{"issue":"6","key":"1525_CR76","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1097\/ALN.0000000000004008","volume":"135","author":"JE Baumgardner","year":"2021","unstructured":"Baumgardner JE, Kretzschmar M, Kozian A, Hachenberg T, Schilling T, Larsson A, et al. Effect of global ventilation to perfusion ratio, for normal lungs, on desflurane and sevoflurane elimination kinetics. Anesthesiology. 2021;135(6):1042\u201354.","journal-title":"Anesthesiology"},{"key":"1525_CR77","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00228-012-1323-5","volume":"69","author":"A Sandqvist","year":"2013","unstructured":"Sandqvist A, Henrohn D, Schneede J, Hedeland M, Eger\u00f6d H, Bondesson UG, et al. High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. Eur J Clin Pharmacol. 2013;69:197\u2013207.","journal-title":"Eur J Clin Pharmacol"},{"key":"1525_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106840","volume":"138","author":"RF Roscigno","year":"2021","unstructured":"Roscigno RF, Vaughn T, Parsley E, Hunt T, Eldon MA, Rubin LJ. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso\u00ae in healthy subjects. Vascul Pharmacol. 2021;138: 106840.","journal-title":"Vascul Pharmacol"},{"issue":"7","key":"1525_CR79","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1743-6109.2009.01403.x","volume":"13","author":"B Berry","year":"2016","unstructured":"Berry B, Altman P, Rowe J, Vaisman J. Comparison of pharmacokinetics of vardenafil administered using an ultrasonic nebulizer for inhalation vs a single 10-mg oral tablet. J Sex Med. 2016;13(7):1111\u20138.","journal-title":"J Sex Med"},{"issue":"1","key":"1525_CR80","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/00498254.2011.626465","volume":"42","author":"RM Jones","year":"2012","unstructured":"Jones RM, Harrison A. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats. Xenobiotica. 2012;42(1):75\u201385.","journal-title":"Xenobiotica"},{"key":"1525_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104553","volume":"84","author":"HI Shahin","year":"2023","unstructured":"Shahin HI, Chablani L. A comprehensive overview of dry powder inhalers for pulmonary drug delivery: challenges, advances, optimization techniques, and applications. J Drug Deliv Sci Technol. 2023;84: 104553.","journal-title":"J Drug Deliv Sci Technol."},{"key":"1525_CR82","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jconrel.2023.01.083","volume":"355","author":"SS Gaikwad","year":"2023","unstructured":"Gaikwad SS, Pathare SR, More MA, Waykhinde NA, Laddha UD, Salunkhe KS, et al. Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies. J Control Release. 2023;355:292\u2013311.","journal-title":"J Control Release"},{"key":"1525_CR83","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","volume":"75","author":"M Hoppentocht","year":"2014","unstructured":"Hoppentocht M, Hagedoorn P, Frijlink H, De Boer A. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014;75:18\u201331.","journal-title":"Adv Drug Deliv Rev"},{"issue":"22","key":"1525_CR84","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1111\/bph.15621","volume":"178","author":"MW Sadiq","year":"2021","unstructured":"Sadiq MW, Holz O, Ellinghusen BD, Faulenbach C, M\u00fcller M, Badorrek P, et al. Lung pharmacokinetics of inhaled and systemic drugs: a clinical evaluation. Br J Pharmacol. 2021;178(22):4440\u201351.","journal-title":"Br J Pharmacol"},{"key":"1525_CR85","first-page":"267","volume-title":"Epithelial permeability and drug absorption in the lungs. Inhaled medicines","author":"Z Enlo-Scott","year":"2021","unstructured":"Enlo-Scott Z, Swedrowska M, Forbes B. Epithelial permeability and drug absorption in the lungs. Inhaled medicines. Amsterdam: Elsevier; 2021. p. 267\u201399."},{"issue":"5","key":"1525_CR86","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1124\/dmd.121.000789","volume":"50","author":"MK Ladumor","year":"2022","unstructured":"Ladumor MK, Unadkat JD. Predicting regional respiratory tissue and systemic concentrations of orally inhaled drugs through a novel PBPK model. Drug Metab Dispos. 2022;50(5):519\u201328.","journal-title":"Drug Metab Dispos"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01525-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T16:02:01Z","timestamp":1750694521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01525-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"1 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by the Chongqing Municipal Education Commission (Grant no. KJ202102858619094) and the National Natural Science Foundation of China (Grant no. 82373966).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yu Lin, Yuanqi Su, Zhongjie Chen, Bing Zhu and Qi Pei have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Yu Lin: conceptualization, writing, funding acquisition and data curation. Yuanqi Su: resources; Zhongjie Chen: software; Bing Zhu: conceptualization, writing and validation. Qi Pei: reviewing, funding acquisition and supervision.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}